Genertec Universal Stock (OTC:UMTAF), Trade Ideas

Genertec Universal Medical Group Co Ltd is principally engaged in providing financing to its customers under finance lease arrangements, the provision of advisory services, the sale of medical equipment as well as leases under operating lease arrangements, and the provision of other services. The Group has two business segments; The finance business comprises direct finance leasing, sale-and-leaseback, factoring, operating leases, and advisory services, and The hospital group business comprises medical services, hospital, and healthcare management, import and export trade, and domestic trade of medical-related goods and life cycle management of equipment assets. Geographically, it derives a majority of its revenue from Mainland China.

News

Intraday Update

Markets

Movers

Trading Ideas

AAPL

AAVXF

ACLS

ADBE

AFGC

AHEXY

AHFD

AINV

AIQUY

ALAC

AMGN

ANSLY

APAM

AQUA

ARES

ARGX

ARNC

ASBFY

ASGN

ASMIY

ASML

ATLKY

AUDC

BABA

BAESF

BAESY

BCLYF

BNPQY

BNTGF

BNTGY

BRPM

BTDPY

BVXV

CARO

CATWF

CBGPY

CBSH

CCGGY

CDMO

CEBUY

CGGYY

CKNHF

CMRE

CODYY

COHU

CRAI

CRARY

CRHCF

CRUS

CSTM

CTIC

CTON

DGDM

DIOD

DKILY

DPSGY

DRNA

DRTGF

DRUNF

DSDVY

DSKIF

DSNKY

Stocks That Hit 52-Week Highs On Friday

GENERTEC UNVL MED GRP CO by Genertec Unvl Med Group Co Ltd.

Genertec Universal Medical Group Co Ltd

Citigroup analyst Atif Malik maintains Silicon Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) with a Neutral and lowers the price target from $137 to $120.

Price Target

Analyst Ratings

SLAB

Citigroup Maintains Neutral on Silicon Laboratories, Lowers Price Target to $120

In a compelling showcase of how sports figures leverage their platforms beyond the field, former NFL athletes <a href="https://www.benzinga.com/general/sports/24/04/38358885/joique-bell-to-discuss-journey-from-rookie-to-prominent-nfl-running-back-at-benzinga-draft-event">Joique Bell</a> and<a href="https://www.benzinga.com/markets/cannabis/24/03/37797148/former-nfl-legends-bring-top-cannabis-strains-to-boston-with-launch-of-primitiv"> Rob Sims</a> shared their philanthropic journeys today (April 25) during the <a href="https://www.youtube.com/watch?v=93htkUYdGNc">Benzinga Sports Business Titans Draft</a> event in Detroit. 
The panel, adjacent to the NFL Draft at Campus Martius, highlighted the transformative impact athletes can have in their communities post-retirement.
<h1 class="wp-block-heading">Athletes Turned Philanthropists</h1>
Moderated by Rachel Decker, president of Detroit Philanthropy, the conversation delved into the personal motivations behind the athletes&#8217; commitments to giving back. 
Bell, a Michigan native and former Detroit Lion, emphasized the influence of his upbringing on his charitable efforts. 
&#8220;Growing up, being involved in community service was ingrained in me by my parents,&#8221; Bell said. He discussed his focus on literacy and education through his foundation, which aims to improve reading levels among students within a short period significantly.
Sims, who transitioned from the gridiron to various business and charitable endeavors, highlighted his strategic approach to philanthropy. 
&#8220;It&#8217;s about making an impact with the resources we have, ensuring our efforts genuinely help those in need,&#8221; Sims stated. His involvement with local organizations such as Detroit PAL and the Children&#8217;s Center demonstrates his commitment to youth and community health.
<h1 class="wp-block-heading">Impact And Influence&nbsp;</h1>
The discussion also covered the athletes&#8217; strategies for selecting and managing philanthropic engagements. 
Both Bell and Sims stressed the importance of aligning with causes that reflect their values and where they can make a meaningful difference. Bell shared his rigorous approach to vetting organizations before partnering with them, ensuring alignment with his goals to support community development.
<h1 class="wp-block-heading">Advice For The Next Generation&nbsp;</h1>
As the event drew the attention of young athletes and aspiring philanthropists, Bell and Sims offered advice on starting and running charitable foundations. 
&#8220;Understand the work that goes into managing a foundation; it&#8217;s akin to running a business,&#8221; Sims advised. Bell echoed this sentiment, emphasizing the importance of commitment and genuine passion for the cause.
<h1 class="wp-block-heading">Legacy Beyond The Field&nbsp;</h1>
Reflecting on their legacies, both athletes expressed a desire to be remembered for their contributions off the field as much as their achievements on it. 
&#8220;It&#8217;s not just about the sports; it&#8217;s about using our platform to make a lasting impact,&#8221; said Bell.
Photo by Dustin Blitchok.

Sports

Events

Game Changers: Ex-NFL Players Talk Philanthropy For Today And Next-Gen At Benzinga Titans Draft Event

Citigroup analyst Ronald Josey maintains Lithia Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAD#NYSE">LAD</a>) with a Neutral and lowers the price target from $320 to $280.

Citigroup Maintains Neutral on Lithia Motors, Lowers Price Target to $280

Citigroup analyst David Lebovitz maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Neutral and lowers the price target from $94 to $91.

BMRN

Citigroup Maintains Neutral on Biomarin Pharmaceutical, Lowers Price Target to $91

Citigroup analyst Michelle Fang maintains New Oriental Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) with a Buy and raises the price target from $66 to $127.

New Oriental Education & Technology Group

Citigroup Maintains Buy on New Oriental Education, Raises Price Target to $127

Citigroup analyst Andrew Kaplowitz maintains Fortive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) with a Buy and lowers the price target from $101 to $98.

Citigroup Maintains Buy on Fortive, Lowers Price Target to $98

Microsoft Sees FY24 Productivity And Business Processes Revenue $19.9B-$20.2B; Intelligent Cloud Revenue $28.4B-$28.7B; More Personal Computing Revenue $15.2B-$15.6B; Cost Of Revenue COGS Of $19.6B-$19.8B; Operating Expenses Of $17.15B-$17.25B; Effective Tax Rate ~18%

Guidance

MSFT

Microsoft Sees FY24 Productivity And Business Processes Revenue $19.9B-$20.2B; Intelligent Cloud Revenue $28.4B-$28.7B; More Personal Computing Revenue $15.2B-$15.6B; Cost Of Revenue COGS Of $19.6B-$19.8B; Operating Expenses Of $17.15B-$17.25B; Effective Tax Rate ~18%

Citigroup analyst Anthony Pettinari maintains Packaging Corp of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) with a Neutral and lowers the price target from $183 to $181.

Citigroup Maintains Neutral on Packaging Corp of America, Lowers Price Target to $181

Citigroup analyst Christopher Allen maintains Virtu Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRT#NASDAQ">VIRT</a>) with a Buy and raises the price target from $22.5 to $24.5.

VIRT

Citigroup Maintains Buy on Virtu Finl, Raises Price Target to $24.5

Citigroup analyst Thomas Palmer maintains Bunge Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) with a Buy and raises the price target from $117 to $122.

Citigroup Maintains Buy on Bunge Global, Raises Price Target to $122

Citigroup analyst Fatima Boolani maintains Fastly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) with a Neutral and lowers the price target from $20 to $15.

FSLY

Citigroup Maintains Neutral on Fastly, Lowers Price Target to $15

Citigroup analyst Fatima Boolani maintains Akamai Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) with a Neutral and lowers the price target from $140 to $117.

AKAM

Citigroup Maintains Neutral on Akamai Techs, Lowers Price Target to $117

Citigroup analyst Joanne Wuensch maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and raises the price target from $79 to $85.

Citigroup Maintains Buy on Boston Scientific, Raises Price Target to $85

Citigroup analyst Patrick Cunningham maintains Sherwin-Williams (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) with a Buy and lowers the price target from $390 to $370.

Citigroup Maintains Buy on Sherwin-Williams, Lowers Price Target to $370

Citigroup analyst Jon Tower maintains Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Buy and raises the price target from $3358 to $3369.

Citigroup Maintains Buy on Chipotle Mexican Grill, Raises Price Target to $3369

Citigroup analyst Jason Gursky maintains Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) with a Buy and lowers the price target from $252 to $224.

Citigroup Maintains Buy on Boeing, Lowers Price Target to $224

Citigroup analyst Andrew Kaplowitz maintains GE Aero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) with a Buy and raises the price target from $120.43 to $186.

Citigroup Maintains Buy on GE Aero, Raises Price Target to $186

Citigroup analyst Jason Gursky maintains General Dynamics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) with a Buy and raises the price target from $300 to $320.

Citigroup Maintains Buy on General Dynamics, Raises Price Target to $320

Citigroup analyst Andrew Kaplowitz maintains Vertiv Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) with a Buy and raises the price target from $102 to $110.

Citigroup Maintains Buy on Vertiv Hldgs, Raises Price Target to $110

Citigroup analyst Atif Malik maintains Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) with a Buy and raises the price target from $975 to $1025.

LRCX

Citigroup Maintains Buy on Lam Research, Raises Price Target to $1025

In a report released on January 1, Chris Lui from Jefferies maintained a Buy rating on Genertec Universal Medical Group Company (UMTAF – Research R...

Jefferies Remains a Buy on Genertec Universal Medical Group Company (UMTAF)

There's a lot to be optimistic about in the Financial sector as 3 analysts just weighed in on AIA Group (AAIGF – Research Report), Genertec Univers...

Analysts Are Bullish on These Financial Stocks: AIA Group (AAIGF), Genertec Universal Medical Group Company (UMTAF)

AAIGF

BNKHF

UMTAF

Genertec Universal